NCT02293720View on ClinicalTrials.gov

An Open-Label Extension to Protocol 09-1, Efficacy and Safety Study of the EndoBarrier® Gastrointestinal Liner System

NAWithdrawnINTERVENTIONAL

Timeline

Start Date

April 30, 2015

Primary Completion Date

July 31, 2016

Study Completion Date

July 31, 2016

Conditions

Type 2 Diabetes

Interventions

DEVICE

EndoBarrier

The EndoBarrier is indicated as an adjunct to diet and exercise to achieve weight loss and improve glycemic control in obese adults with type 2 diabetes whose anti-diabetes medications have not achieved adequate glycemic control.